PATENT CLAIM ANALYSIS

Application Number: 16148825
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["514", "651000"]

Abstract:
The present invention is directed to pharmaceutical compositions and methods of treating traumatic brain injury (TBI). The invention is also directed to pharmaceutical compositions and methods of treating a transient hypoxic and/or ischemic condition in the central nervous system. More specifically, the present invention is directed to pharmaceutical compositions and methods of reducing the occurrence of neuronal cell death in the central nervous system, such as, reducing the occurrence brain cell death in the hippocampus and/or the cortex.

Claim (Index 10):
The method according to any one of the preceding claims, wherein the haloalkylamine is in unit dosage amounts of about 0.5 mg/kg body weight to about 20 mg/kg body weight.

Metadata:
- Claim Count in Document: 107.0
- Percentile: 97.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14911943', '14002429', '13175518', '13621977', '14426832']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7879289904336866
- 35 USC 102 Novelty (BERT): 0.5259896426241016
- Combined Prediction Score: 0.7617350556527281
- Mean Citation Score: 301.7414760000001
- Max Citation Score: 315.034
- Similarity Product: 186.59454362154003

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test